艾沙康唑治疗播散性毛霉病患者。
Isavuconazole treatment of a patient with disseminated mucormycosis.
作者信息
Peixoto Driele, Gagne Lisa S, Hammond Sarah P, Gilmore Erin T, Joyce Amy C, Soiffer Robert J, Marty Francisco M
机构信息
Division of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
出版信息
J Clin Microbiol. 2014 Mar;52(3):1016-9. doi: 10.1128/JCM.03176-13. Epub 2014 Jan 8.
Abstract
We report a patient with relapsed acute myelogenous leukemia after allogeneic stem cell transplantation who developed disseminated mucormycosis due to Rhizomucor pusillus/R. miehei involving lung, brain, and skin. After failing posaconazole and being intolerant to amphotericin, he was treated effectively with isavuconazole for over 6 months despite ongoing treatment for relapsed leukemia.
摘要
我们报告了1例异基因干细胞移植后复发的急性髓系白血病患者，其因米根霉/米黑根毛霉感染发生播散性毛霉病，累及肺、脑和皮肤。在泊沙康唑治疗失败且对两性霉素不耐受后，尽管其复发的白血病仍在持续治疗，但他接受了6个多月的艾沙康唑治疗，效果良好。
相似文献
1
Isavuconazole treatment of a patient with disseminated mucormycosis.艾沙康唑治疗播散性毛霉病患者。
J Clin Microbiol. 2014 Mar;52(3):1016-9. doi: 10.1128/JCM.03176-13. Epub 2014 Jan 8.
2
Cerebral Rhizomucor Infection Treated by Posaconazole Delayed-Release Tablets in an Allogeneic Stem Cell Transplant Recipient.泊沙康唑缓释片治疗异基因干细胞移植受者的脑根霉感染
Int J Infect Dis. 2017 Feb;55:24-26. doi: 10.1016/j.ijid.2016.12.014. Epub 2016 Dec 14.
3
Successful treatment of disseminated mucormycosis with a combination of liposomal amphotericin B and posaconazole in a patient with acute myeloid leukaemia.脂质体两性霉素B与泊沙康唑联合成功治疗1例急性髓系白血病合并播散性毛霉菌病患者
Mycoses. 2006;49 Suppl 1:27-30. doi: 10.1111/j.1439-0507.2006.01299.x.
4
Successful isavuconazole salvage therapy in a patient with invasive mucormycosis.侵袭性毛霉病患者成功接受艾沙康唑挽救治疗。
Infection. 2014 Apr;42(2):429-32. doi: 10.1007/s15010-013-0552-6. Epub 2013 Nov 12.
5
Successful outcome of disseminated mucormycosis in a 3-year-old child suffering from acute leukaemia: the role of isavuconazole? A case report.一名患有急性白血病的3岁儿童播散性毛霉病的成功治疗结果：艾沙康唑的作用？病例报告。
BMC Pharmacol Toxicol. 2018 Dec 6;19(1):81. doi: 10.1186/s40360-018-0273-7.
6
Cutaneous mucormycosis.皮肤毛霉病
Transpl Infect Dis. 2019 Apr;21(2):e13039. doi: 10.1111/tid.13039. Epub 2019 Jan 4.
7
Prophylaxis with Isavuconazole or Posaconazole Protects Immunosuppressed Mice from Pulmonary Mucormycosis.使用艾沙康唑或泊沙康唑进行预防可保护免疫抑制小鼠免受肺毛霉病感染。
Antimicrob Agents Chemother. 2017 Apr 24;61(5). doi: 10.1128/AAC.02589-16. Print 2017 May.
8
Successful treatment of invasive mucormycosis with isavuconazole in pediatric patients.儿童患者使用伊曲康唑成功治疗侵袭性毛霉菌病。
Pediatr Blood Cancer. 2018 Oct;65(10):e27281. doi: 10.1002/pbc.27281. Epub 2018 Jun 22.
9
Isolated cerebral mucormycosis caused by .由……引起的孤立性脑毛霉菌病。 （原文句子不完整，翻译可能不太准确，完整准确翻译需补充完整原文）
BMJ Case Rep. 2017 Oct 4;2017:bcr-2017-221473. doi: 10.1136/bcr-2017-221473.
10
Breaking the Mold: A Review of Mucormycosis and Current Pharmacological Treatment Options.打破常规：毛霉病及当前药物治疗选择综述
Ann Pharmacother. 2016 Sep;50(9):747-57. doi: 10.1177/1060028016655425. Epub 2016 Jun 15.
引用本文的文献
1
Use of isavuconazole in mucormycosis: a systematic review.艾沙康唑在毛霉病中的应用：一项系统评价。
BMC Infect Dis. 2025 Jan 6;25(1):25. doi: 10.1186/s12879-025-10439-y.
2
Mucormycosis: A hidden mystery of fungal infection, possible diagnosis, treatment and development of new therapeutic agents.毛霉菌病：真菌感染的隐藏谜团，可能的诊断、治疗和新治疗药物的研发。
Eur J Med Chem. 2023 Jan 15;246:115010. doi: 10.1016/j.ejmech.2022.115010. Epub 2022 Dec 10.
3
Successful long-term therapy of mucormycosis with isavuconazole.用艾沙康唑成功进行毛霉菌病的长期治疗。
Proc (Bayl Univ Med Cent). 2021 Jun 15;34(6):703-704. doi: 10.1080/08998280.2021.1935138. eCollection 2021.
4
Left hand necrosis as the initial presentation of disseminated mucormycosis: A case report and literature review.左手坏死作为播散性毛霉病的首发表现：一例病例报告及文献综述
IDCases. 2021 Aug 31;26:e01269. doi: 10.1016/j.idcr.2021.e01269. eCollection 2021.
5
COVID-19 associated mucormycosis: the urgent need to reconsider the indiscriminate use of immunosuppressive drugs.新型冠状病毒肺炎相关毛霉菌病：迫切需要重新审视免疫抑制药物的滥用问题。
Ther Adv Infect Dis. 2021 Jun 18;8:20499361211027065. doi: 10.1177/20499361211027065. eCollection 2021 Jan-Dec.
6
Mucormycosis.毛霉菌病。
Infect Dis Clin North Am. 2021 Jun;35(2):435-452. doi: 10.1016/j.idc.2021.03.009.
7
Disseminated Mucormycosis in Immunocompromised Children: Are New Antifungal Agents Making a Difference? A Multicenter Retrospective Study.免疫功能低下儿童的播散性毛霉菌病：新型抗真菌药物是否发挥了作用？一项多中心回顾性研究。
J Fungi (Basel). 2021 Feb 25;7(3):165. doi: 10.3390/jof7030165.
8
Rhino-orbital mucormycosis due to Apophysomyces ossiformis in a patient with diabetes mellitus: a case report.一名糖尿病患者因骨状附孢霉引起的鼻眶毛霉病：病例报告
BMC Infect Dis. 2020 Aug 18;20(1):614. doi: 10.1186/s12879-020-05337-4.
9
Extrapolating Antifungal Animal Data to Humans - Is it reliable?将抗真菌动物实验数据外推至人类——这可靠吗？
Curr Fungal Infect Rep. 2020 Mar;14(1):50-62. doi: 10.1007/s12281-020-00370-x. Epub 2020 Jan 16.
10
Cutaneous mucormycosis by treated with isavuconazole as first line therapy: A case report.以艾沙康唑作为一线治疗的皮肤毛霉病：一例报告
Med Mycol Case Rep. 2019 Oct 3;26:42-43. doi: 10.1016/j.mmcr.2019.10.002. eCollection 2019 Dec.
本文引用的文献
1
Successful isavuconazole salvage therapy in a patient with invasive mucormycosis.侵袭性毛霉病患者成功接受艾沙康唑挽救治疗。
Infection. 2014 Apr;42(2):429-32. doi: 10.1007/s15010-013-0552-6. Epub 2013 Nov 12.
2
Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections.评估伊曲康唑治疗侵袭性真菌感染的药代动力学和临床实用性。
Expert Opin Drug Metab Toxicol. 2012 Jun;8(6):759-65. doi: 10.1517/17425255.2012.683859. Epub 2012 Apr 25.
3
Mortality in hematologic malignancy and hematopoietic stem cell transplant patients with mucormycosis, 2001 to 2009.2001 年至 2009 年血液恶性肿瘤和造血干细胞移植患者中毛霉菌病的死亡率。
Antimicrob Agents Chemother. 2011 Nov;55(11):5018-21. doi: 10.1128/AAC.00536-11. Epub 2011 Aug 29.
4
Molecular methods to improve diagnosis and identification of mucormycosis.提高毛霉病诊断和鉴定的分子方法。
J Clin Microbiol. 2011 Jun;49(6):2151-3. doi: 10.1128/JCM.00256-11. Epub 2011 Apr 20.
5
Novel triazole antifungal drugs: focus on isavuconazole, ravuconazole and albaconazole.新型三唑类抗真菌药物：聚焦于艾沙康唑、雷夫康唑和阿巴康唑。
Curr Opin Investig Drugs. 2010 Feb;11(2):165-74.
6
Limited penetration of posaconazole into cerebrospinal fluid in an allogeneic stem cell recipient with invasive pulmonary aspergillosis.泊沙康唑在一名患有侵袭性肺曲霉病的异基因干细胞受体的脑脊液中渗透有限。
Bone Marrow Transplant. 2009 Aug;44(4):269-70. doi: 10.1038/bmt.2009.17. Epub 2009 Feb 16.
7
Antifungal therapeutic drug monitoring: established and emerging indications.抗真菌治疗药物监测：既定及新出现的适应证
Antimicrob Agents Chemother. 2009 Jan;53(1):24-34. doi: 10.1128/AAC.00705-08. Epub 2008 Oct 27.
8
Posaconazole concentrations in the central nervous system.泊沙康唑在中枢神经系统中的浓度。
J Antimicrob Chemother. 2008 Dec;62(6):1468-70. doi: 10.1093/jac/dkn409. Epub 2008 Sep 28.
9
In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.艾沙康唑（BAL4815）、伏立康唑和氟康唑对1007株接合菌、念珠菌、曲霉菌、镰刀菌和赛多孢子菌属菌株的体外抗真菌活性。
Antimicrob Agents Chemother. 2008 Apr;52(4):1396-400. doi: 10.1128/AAC.01512-07. Epub 2008 Jan 22.
10
New and emerging treatments for fungal infections.真菌感染的新型及新兴治疗方法。
J Antimicrob Chemother. 2008 Jan;61 Suppl 1:i19-30. doi: 10.1093/jac/dkm428.
Zotero 插件